Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious dogs underwent euglycemic clamps with tracer and hepatic balance measurements. Clamp period infusions were peripheral venous regular insulin (0.1 nmol ⋅ kg(−1) ⋅ h(−1) [co...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Mary Courtney, Smith, Marta S., Sinha, Vikram P., Beals, John M., Michael, M. Dodson, Jacober, Scott J., Cherrington, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2014
Materias:
Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361402/
https://www.ncbi.nlm.nih.gov/pubmed/24089512
http://dx.doi.org/10.2337/db13-0826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361402/
https://www.ncbi.nlm.nih.gov/pubmed/24089512
http://dx.doi.org/10.2337/db13-0826

Ejemplares similares